Argentina Slams US Decision On Sanctions

27 January 1997

Argentine President Carlos Menem has described as "unjust" the USdecision to withdraw 50% of Argentina's duty-free privileges in the US market, in a move aimed at pressuring Argentina into modifying its patent laws (Marketletter January 20).

Speaking on television, Pres Menem said acting US Trade Representative Charlene Barshefsky's announcement of the US decision to place higher tariffs on $260 million worth of imports from Argentina under the Generalized System of Preferences was "a completely unfair sanction which does not agree with reality." Implementation is suspended until March 1, to give time for negotiation. Pres Menem said the move will not damage bilateral regulations, and Argentina will seek to settle through dialogue.

The Argentine industry association Cilfa said the move was "an unwarranted attack" brought on by the US Administration "bowing to the heavy-handed lobbying by the Pharmaceutical Research and Manufacturers of America." This is the second time since the Uruguay Round of the General Agreement on Tariffs and Trade that drug multinationals have "dictated US trade policy to line their own pockets at the expense of consumers," it says.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight